VCA Stocks

Inimex Pharmaceuticals, Inc. is pleased to announce the closing of a US $22 Million Series B venture financing.  The funds will enable Inimex to conduct the first clinical trials of an Innate Defense Regulator (IDR) drug in patients and to evaluate IDR drugs in a broad range of disease models. IDRs are novel drugs that selectively trigger the body’s innate defenses, protecting against antibiotic-resistant infections and controlling inflammation.  “We believe IDR peptides will have broad application in patients of all ages, acting against infections associated with cystic fibrosis, pneumonia, inflammation and in cancer patients undergoing chemotherapy,” said North. “We are in desperate need of a new approach to treatments of superbugs because the antibiotic resistance problem is rapidly becoming more prevalent.”